KOSDAQElectrical Equipment450950

Asterasys

₩4,905▲ 2.19%2026-11-18 close
Market Cap
₩184.6B
Turnover
₩28,789,610
Volume
6K
Shares out.
37.6M
PER
56.8×
PBR
4.2×
EPS
₩88
Dividend Yield
2.10%

PER, EPS, PBR and BPS are calculated in-house from the last 4 quarters (2025Q4–2026Q3) · Dividend yield is based on ₩105 per share · Prices as of the 2026-11-18 close

01

Report overview

US clearance and consumables will shape the next phase

Filed results show revenue and operating profit rising together from 2023 to 2025, but quarterly results in 2026 alternated between operating losses and operating profits, leaving US market execution as the key variable.

  1. 1

    On a filed basis, revenue rose from KRW 17.5 billion in 2023 to KRW 37.9 billion in 2025, and operating margin climbed from 8.9% to 27.4%.

  2. 2

    The first quarter of 2026 posted an operating loss of KRW 1.78 billion, the second quarter returned to operating profit of KRW 79.28 million, and third-quarter operating profit of KRW 440 million fell 80.9% year on year.

  3. 3

    Controlling-shareholder net loss in the third quarter of 2026 was KRW 912 million, a swing from profit a year earlier.

  4. 4

    Coolfase received US FDA clearance in October 2025, and a US clearance target for CoolSoniq was set for mid-2026.

  5. 5

    A domestic brokerage said in a June 2026 report that it lowered its target price from KRW 16,000 to KRW 13,000, citing stalled sales and higher selling and administrative expenses.

02

Business structure

Asterasys is a aesthetic medical device company founded in 2015, built around the high-intensity focused ultrasound (HIFU) device 'Liftera', the HIFU device 'CoolSoniq', and the monopolar radiofrequency (RF) device 'Coolfase'.

Coverage at the time of its listing put HIFU devices at 91% of 2023 sales, RF devices at 2.5%, and skincare products at 4.0%. Consumables sales rise with the number of treatments performed on installed devices, and materials from the same period put the consumables share at 67.2% of total sales.

A first-half 2026 brokerage report estimated 2025 consumables sales at KRW 24.2 billion, up 36.0%. Overseas sales were described as about 70% of the total, and as of the third quarter of 2024 regional sales were 41% South America, 28% Korea and 26% Asia.

CoolSoniq launched in Korea in the second quarter of 2025, and the company says its selling price is twice that of Liftera while its cost ratio is about 20% versus roughly 30% for Liftera.

Coolfase expanded into Brazil, Taiwan, Indonesia and Thailand after its domestic approval and received US FDA clearance in October 2025. The company positions itself as a late entrant that differentiates through cooling technology and a consumables-driven revenue model.

03

Earnings trend

Quarterly revenue · Operating profit
RevenueOperating profit
Annual revenue · Operating profit
RevenueOperating profit
Quarterly results · Last 5 quarters
QuarterRevenueOperating profitOp. margin
2025Q3₩8.8B₩2.3B26.3%
2025Q4₩12.2B₩3.7B30.1%
2026Q1₩7.5B-₩1.8B−23.9%
2026Q2₩11.2B₩79,277,6370.7%
2026Q3₩9B₩400M4.9%
Annual results
YearRevenueOperating profitNet income (parent)Op. marginROEDebt-to-equity
2023₩17.5B₩1.6B₩900M8.9%13.0%147.1%
2024₩28.8B₩6.7B₩5.4B23.1%27.3%25.9%
2025₩37.9B₩10.4B₩9.2B27.4%19.7%11.7%

Consolidated basis (financial statements including subsidiaries) · Final figures from DART filings · Net income attributable to owners of the parent · Data as of 2026-11-13

04

Earnings analysis

On a filed basis, annual revenue was KRW 17.5 billion in 2023, KRW 28.8 billion in 2024 (up 64.8% year on year) and KRW 37.9 billion in 2025 (up 31.6%). Revenue grew for two consecutive years from 2024 through 2025, and 2025 was the largest year of the 2023–2025 period.

Operating profit was KRW 1.56 billion in 2023, KRW 6.66 billion in 2024 (up 328.6%) and KRW 10.4 billion in 2025 (up 55.9%). Operating margin moved from 8.9% to 23.1% and then 27.4%, so profit grew faster than sales.

In its first-half 2025 results, the company credited a richer product mix from Coolfase consumables and the higher share of the premium CoolSoniq. Profit attributable to controlling shareholders was KRW 872 million in 2023, KRW 5.35 billion in 2024 (up 513.9%) and KRW 9.21 billion in 2025 (up 72.1%).

Net income including non-controlling interests was reported at the same amounts in each year. Operating cash flow rose from KRW 1.48 billion to KRW 4.36 billion and then KRW 4.99 billion, and the debt ratio fell from 147.1% to 11.7%.

At the end of 2025, total equity was KRW 46.8 billion, all of it controlling-shareholder equity, and total liabilities were KRW 5.45 billion. The quarterly path was less steady.

The third quarter of 2025 showed revenue of KRW 8.75 billion, operating profit of KRW 2.3 billion and controlling-shareholder profit of KRW 1.91 billion. The fourth quarter peaked at revenue of KRW 12.2 billion (up 39.0% quarter on quarter) and operating profit of KRW 3.66 billion (up 59.0%).

Revenue fell 38.6% to KRW 7.47 billion in the first quarter of 2026, which posted an operating loss of KRW 1.78 billion and a controlling-shareholder net loss of KRW 960 million.

A domestic brokerage said the same quarter saw a sharp drop in Coolfase exports to Brazil and higher selling and administrative expenses such as domestic advertising.

The second quarter returned to profit, with revenue of KRW 11.2 billion (up 50.2%), operating profit of KRW 79.28 million and controlling-shareholder profit of KRW 1.3 billion.

The third quarter of 2026 brought revenue of KRW 9.02 billion (down 19.6% quarter on quarter, up 3.1% year on year) and operating profit of KRW 440 million (down 80.9% year on year). Controlling-shareholder net loss of KRW 912 million turned a year-earlier profit into a loss.

Over the last four quarters, controlling-shareholder profit totaled KRW 3.27 billion. A brokerage also linked the third quarter of 2025 slowdown to Brazil's seasonal treatment pattern.

05

Industry analysis

The aesthetic device market is growing on rising treatment demand. A market research firm's estimate put the US dermatology aesthetic device market at USD 13.7 billion in 2022, with the global market projected to reach USD 145.7 billion by 2030.

These figures are third-party projections and may diverge from actual growth. A domestic brokerage noted in a June 2026 report that the aesthetic device sector was in a correction. The company says that CoolSoniq is capturing both new and replacement demand in the domestic premium HIFU segment.

A company representative said CoolSoniq and Liftera differ in performance, target customers and price, so Liftera replacement demand would not translate directly into CoolSoniq sales. In competitive terms, a brokerage in November 2025 said the company achieved technology differentiation despite being a late entrant.

WON Tech is often compared with Asterasys within the same aesthetic device industry. Overseas sales span 62 countries, but South American treatment seasonality affects the pattern.

The US is the largest market, and the company's plan calls for North American revenue to build once local distributor selection is complete.

06

Outlook

The company set 2026 goals of bringing Coolfase to the US and obtaining US clearance for CoolSoniq. A January 2026 report put the CoolSoniq clearance target in mid-2026, with a decision possibly as early as within 2026. The company also planned to widen its footprint to Vietnam and parts of South America in 2026.

Its 2025 plans targeted entry into Europe and China in 2027. At the end of 2025, the company said it aimed for an improved profit margin in 2026 versus 2025.

The 2025 operating margin was 27.4%, while the first quarter of 2026 posted an operating loss, the second quarter a profit, and the third quarter operating profit of KRW 440 million. A first-half 2026 brokerage report estimated first-quarter revenue at KRW 9.1 billion, versus filed revenue of KRW 7.47 billion.

The same report estimated 2026 consumables sales growth of 36.9%. Brokerages expected margins to improve gradually from the second half as high-margin product sales rose. The next checkpoint is whether the 2026 annual report shows an operating margin above the 27.4% recorded in 2025.

07

Valuation

PER
56.8×
PBR
4.2×
ROE
7.5%
EPS
₩88
BPS
₩1,202
Dividend per share
₩105

Valuation reads as a market capitalization large relative to both earnings and net assets. Controlling-shareholder profit over the last four quarters totaled KRW 3.27 billion, and the market capitalization is several tens of times that figure.

Against total equity of KRW 46.8 billion, the price-to-book ratio sits in a premium range. In early 2026, brokerages compared the stock's multiples with those of aesthetic device peers such as Classys and WON Tech, finding it higher, and some argued that growth had been priced in before results were proven.

Quarterly profit has moved between losses and profits, which widens the range of interpretation for multiples. If profit recovers, the same share price would imply a lower multiple. Over several years, profit rose steadily through 2025 before quarterly results turned volatile in 2026.

Because multiples change with the share price, reading them alongside the earnings trend and the position relative to net assets gives the clearer picture.

PER, EPS, PBR and BPS are all calculated in-house (the same method as Naver and Toss) · Dividend yield = cash dividend per share from DART filings (supplemented by KRX) ÷ current price · As of 2026-11-13

08

Bull factors

US channel expansion after clearance

Coolfase received US FDA clearance in October 2025, establishing the basis for North American sales. The company said it planned to finish selecting local distributors in the first half of 2026 to speed up North American revenue.

If CoolSoniq's US clearance arrives on the mid-2026 target, device sales and consumables could rise together, according to brokerage views.

Margin improvement structure

Operating margin rose from 8.9% in 2023 to 27.4% in 2025. The company explains that CoolSoniq, priced above Liftera with a lower cost ratio, contributes to a better product mix. Fourth-quarter 2025 operating profit of KRW 3.66 billion was the highest among the filed quarters.

Expanded financial capacity

The debt ratio fell from 147.1% in 2023 to 11.7% in 2025. Total liabilities at the end of 2025 were KRW 5.45 billion, against total equity of KRW 46.8 billion. Operating cash flow also rose from KRW 1.48 billion in 2023 to KRW 4.99 billion in 2025. This financial capacity could reduce the funding burden of overseas expansion.

09

Bear factors

Volatile quarterly profit in 2026

Operating loss of KRW 1.78 billion in the first quarter of 2026 and a controlling-shareholder net loss of KRW 912 million in the third quarter show losses recurring. Controlling-shareholder profit over the last four quarters totaled KRW 3.27 billion, a modest figure. The lack of a clear quarterly direction is the main bearish factor.

Selling expense burden and export swings

A domestic brokerage attributed first-quarter stalled sales to a sharp drop in Coolfase exports to Brazil, and the operating loss to higher selling expenses from domestic marketing such as TV advertising. Sangsangin Securities lowered its target price from KRW 16,000 to KRW 13,000 in June 2026. Brazilian treatment seasonality also reduced South American sales in the third quarter of 2025.

Expectations concentrated on US results

A January 2026 brokerage analysis said CoolSoniq's domestic sales growth and the outcome of its US clearance would weigh heavily on enterprise value. If the US clearance timetable slips, the start of US revenue could also be pushed back. Expectations are concentrated on US results, so a delay could affect both sentiment and earnings estimates.

10

Risk factors

Regulatory and clearance

The timing and outcome of CoolSoniq's US FDA clearance are not yet set. A delay would limit growth to Coolfase's US sales alone. Even after clearance, building local distribution and promotion costs could weigh on results.

Overseas demand and regional concentration

As of the third quarter of 2024, South America accounted for the largest regional share of sales at 41%. In the first quarter of 2026, a sharp drop in Coolfase exports to Brazil was cited as a cause of weak sales.

Even as the number of sales countries grows, dependence on a few regions keeps quarterly results exposed to seasonality and local demand swings.

Cost structure and multiple volatility

Expanded marketing and selling expenses could pressure operating margin. The company aimed for a better margin in 2026 through operating leverage, yet quarterly results have diverged from that path.

With the market capitalization large relative to earnings, volatile quarterly profit widens the range of multiple interpretations.

11

What to watch next

  1. After Q4 2026 (timing not set)

    The outcome of CoolSoniq's US FDA clearance decision and whether Coolfase US sales begin. Clearance and the scale of US revenue are the largest variables for earnings expectations.

  2. End of March 2027 (statutory deadline for the annual report)

    The 2026 annual report. Whether the 2026 full-year operating margin exceeds the 27.4% recorded in 2025 is the next checkpoint. Changes in consumables sales and regional sales mix will also come into view.

  3. May 15, 2027 (statutory deadline for the first-quarter report)

    First-quarter 2027 results. Whether US revenue has begun and whether the selling expense trend that followed the first-quarter 2026 operating loss has eased are the points to check.

  4. During 2027 (target year)

    Progress on the Europe and China entry targets. Whether the market expansion set for 2027 is executed will shape the medium-term growth path.

12

Overall view

Filed results show Asterasys's revenue, operating profit and controlling-shareholder profit all rising from 2023 to 2025, with operating margin climbing from 8.9% to 27.4%. The debt ratio also improved from 147.1% to 11.7%.

In 2026, however, quarterly results became volatile: an operating loss of KRW 1.78 billion in the first quarter, a return to profit in the second, and a controlling-shareholder net loss of KRW 912 million in the third. Controlling-shareholder profit over the last four quarters totaled KRW 3.27 billion.

Bullish factors include Coolfase's US clearance, the product mix gains from CoolSoniq, the consumables structure and financial capacity. Bearish factors include selling expense pressure, export volatility in specific regions such as Brazil, and uncertainty over the timing of CoolSoniq's US clearance.

Brokerage target prices have moved in both directions, and a domestic brokerage lowered its target in June 2026. The next checkpoints are the outcome of CoolSoniq's US clearance and the 2026 full-year operating margin in the annual report.

13

Sources

  1. Korea Exchange (KRX) — Prices · Market Cap · Volume
  2. FSS electronic disclosure system (DART) — Financial statements · Dividend filings
Show 16 more articles and sources
  1. newstopkorea.com
  2. mt.co.kr
  3. v.daum.net
  4. pharmnews.com
  5. m.thinkpool.com
  6. hitnews.co.kr
  7. pharm.edaily.co.kr
  8. dailyinvest.kr
  9. pharmnews.com
  10. m.news.nate.com
  11. file.alphasquare.co.kr
  12. newspim.com
  13. investing.com
  14. valueline.co.kr
  15. dailyinvest.kr
  16. investing.com

Report written 2026-11-14 · Data as of 2026-11-13

This content is AI analysis of market data and web search results, provided for information only. It is not a solicitation or recommendation to invest. Investment decisions and their consequences are the investor's own responsibility. Data may be delayed or contain errors.

Other reports in this industry

View industry analysis